

Rhoda E Kuc

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9418541/publications.pdf>

Version: 2024-02-01

61
papers

2,452
citations

218592

26
h-index

197736

49
g-index

65
all docs

65
docs citations

65
times ranked

2755
citing authors

#	ARTICLE	IF	CITATIONS
1	Endothelin-1 is increased in the plasma of patients hospitalised with Covid-19. <i>Journal of Molecular and Cellular Cardiology</i> , 2022, 167, 92-96.	0.9	19
2	Apelin is expressed throughout the human kidney, is elevated in chronic kidney disease & associates independently with decline in kidney function. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 5295-5306.	1.1	3
3	Plasma levels of apelin are reduced in patients with liver fibrosis and cirrhosis but are not correlated with circulating levels of bone morphogenetic protein 9 and 10. <i>Peptides</i> , 2021, 136, 170440.	1.2	7
4	Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection. <i>Communications Biology</i> , 2021, 4, 926.	2.0	11
5	FXR antagonists as new agents for COVID19. , 2021, , .		1
6	In vitro metabolism of synthetic Elabela/Toddler (ELA-32) peptide in human plasma and kidney homogenates analyzed with mass spectrometry and validation of endogenous peptide quantification in tissues by ELISA. <i>Peptides</i> , 2021, 145, 170642.	1.2	2
7	Differential expression in humans of the viral entry receptor ACE2 compared with the short deltaACE2 isoform lacking SARS-CoV-2 binding sites. <i>Scientific Reports</i> , 2021, 11, 24336.	1.6	12
8	Apelin peptides linked to anti-serum albumin domain antibodies retain affinity in vitro and are efficacious receptor agonists in vivo. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 126, 96-103.	1.2	14
9	The G Protein Biased Small Molecule Apelin Agonist CMF-019 is Disease Modifying in Endothelial Cell Apoptosis In Vitro and Induces Vasodilatation Without Desensitisation In Vivo. <i>Frontiers in Pharmacology</i> , 2020, 11, 588669.	1.6	7
10	Apelin-36-[L28A] and Apelin-36-[L28C(30kDa-PEG)] peptides that improve diet induced obesity are G protein biased ligands at the apelin receptor. <i>Peptides</i> , 2019, 121, 170139.	1.2	10
11	A novel cyclic biased agonist of the apelin receptor, MM07, is disease modifying in the rat monocrotaline model of pulmonary arterial hypertension. <i>British Journal of Pharmacology</i> , 2019, 176, 1206-1221.	2.7	32
12	BS49...Human embryonic stem cell derived cardiomyocytes express functional receptors for the cardiovascular peptide apelin. , 2019, , .		0
13	BS46...High content high resolution confocal imaging to characterise mutations in the apelin receptor identified in patients from the 100,000 genomes project. , 2019, , .		0
14	Development and validation of an LC-MS/MS method for detection and quantification of in vivo derived metabolites of [Pyr1]apelin-13 in humans. <i>Scientific Reports</i> , 2019, 9, 19934.	1.6	14
15	Biased apelin receptor agonists for cardiovascular disease. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, SY85-1.	0.0	0
16	Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial Hypertension. <i>Circulation</i> , 2017, 135, 1160-1173.	1.6	183
17	Detection of Atherosclerotic Inflammation by 68 Ga-DOTATATE PET Compared to [18 F]FDG PET Imaging. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1774-1791.	1.2	321
18	Smooth Muscle Endothelin B Receptors Regulate Blood Pressure but Not Vascular Function or Neointimal Remodeling. <i>Hypertension</i> , 2017, 69, 275-285.	1.3	12

#	ARTICLE	IF	CITATIONS
19	Dâ€...Atherosclerotic inflammation imaging using ⁶⁸ ga-dotatate pet vs. ¹⁸ f-fdg pet: a prospective clinical study with molecular and histological validation. <i>Heart</i> , 2017, 103, A151.2-A152.	1.2	0
20	[Pyr1]Apelin-13(1â€12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13. <i>Frontiers in Neuroscience</i> , 2017, 11, 92.	1.4	46
21	Cardiac action of the first G protein biased small molecule apelin agonist. <i>Biochemical Pharmacology</i> , 2016, 116, 63-72.	2.0	56
22	Chemerin Elicits Potent Constrictor Actions via Chemokineâ€Like Receptor 1 (CMKLR1), not Gâ€Proteinâ€Coupled Receptor 1 (GPR1), in Human and Rat Vasculature. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	67
23	Endothelin ET A receptors predominate in chronic thromboembolic pulmonary hypertension. <i>Life Sciences</i> , 2016, 159, 104-110.	2.0	13
24	The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro. <i>Cardiovascular Research</i> , 2014, 101, 513-521.	1.8	21
25	Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension. <i>Life Sciences</i> , 2014, 118, 391-396.	2.0	13
26	Characterization of [125I]GLP-1(9-36), a novel radiolabeled analog of the major metabolite of glucagon-like peptide 1 to a receptor distinct from GLP1-R and function of the peptide in murine aorta. <i>Life Sciences</i> , 2014, 102, 134-138.	2.0	10
27	No evidence for a local renin-angiotensin system in liver mitochondria. <i>Scientific Reports</i> , 2013, 3, 2467.	1.6	12
28	Radioligand Binding Assays and Their Analysis. <i>Methods in Molecular Biology</i> , 2012, 897, 31-77.	0.4	86
29	Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice. <i>Life Sciences</i> , 2012, 91, 716-722.	2.0	18
30	Comparison of human ETA and ETB receptor signalling via G-protein and Î²-arrestin pathways. <i>Life Sciences</i> , 2012, 91, 544-549.	2.0	27
31	The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans. <i>Life Sciences</i> , 2012, 91, 743-748.	2.0	22
32	Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues. <i>Life Sciences</i> , 2012, 91, 681-686.	2.0	24
33	Cellular Localization of Receptors Using Antibodies Visualized by Light and Dual Labeling Confocal Microscopy. <i>Methods in Molecular Biology</i> , 2012, 897, 239-260.	0.4	1
34	Endothelin Receptor Distribution In Pulmonary Endarterectomy Tissue. , 2011, , .		0
35	Inotropic Action of the Puberty Hormone Kisspeptin in Rat, Mouse and Human: Cardiovascular Distribution and Characteristics of the Kisspeptin Receptor. <i>PLoS ONE</i> , 2011, 6, e27601.	1.1	24
36	Evidence for a novel vasospastic transmitter system, neuromedin U, in the equine digital circulation. <i>Veterinary Journal</i> , 2010, 186, 106-109.	0.6	1

#	ARTICLE	IF	CITATIONS
37	Modulation of the apelin/APJ system in heart failure and atherosclerosis in man. <i>British Journal of Pharmacology</i> , 2010, 160, 1785-1795.	2.7	84
38	Immunocytochemical localization of the urotensin-II receptor, UT, to rat and human tissues: Relevance to function. <i>Peptides</i> , 2008, 29, 735-742.	1.2	30
39	Expression and vasoconstrictor function of anorexigenic peptides neuromedin U-25 and S in the human cardiovascular system. <i>Cardiovascular Research</i> , 2008, 81, 353-361.	1.8	33
40	Kisspeptins Are Novel Potent Vasoconstrictors in Humans, with a Discrete Localization of Their Receptor, G Protein-Coupled Receptor 54, to Atherosclerosis-Prone Vessels. <i>Endocrinology</i> , 2007, 148, 140-147.	1.4	128
41	Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation. <i>British Journal of Pharmacology</i> , 2006, 147, 612-621.	2.7	19
42	Novel Snake Venom Ligand Dendroaspis Natriuretic Peptide Is Selective for Natriuretic Peptide Receptor-A in Human Heart. <i>Circulation Research</i> , 2006, 99, 183-190.	2.0	67
43	Quantification of endothelin receptor subtypes in peripheral tissues reveals downregulation of ET(A) receptors in ET(B)-deficient mice. <i>Experimental Biology and Medicine</i> , 2006, 231, 741-5.	1.1	13
44	Radioligand-Binding and Molecular-Imaging Techniques for the Quantitative Analysis of Established and Emerging Orphan Receptor Systems. , 2005, 306, 093-120.		13
45	Identification and cellular localisation of NPW1 (GPR7) receptors for the novel neuropeptide W-23 by [125I]-NPW radioligand binding and immunocytochemistry. <i>Brain Research</i> , 2004, 1017, 222-226.	1.1	49
46	Cellular distribution of immunoreactive urotensin-II in human tissues with evidence of increased expression in atherosclerosis and a greater constrictor response of small compared to large coronary arteries. <i>Peptides</i> , 2004, 25, 1767-1774.	1.2	106
47	Comparison of Endothelin-A and Endothelin-B Receptor Distribution Visualized by Radioligand Binding versus Immunocytochemical Localization using Subtype Selective Antisera. <i>Journal of Cardiovascular Pharmacology</i> , 2004, 44, S224-S226.	0.8	40
48	Immunocytochemical Localization of Endothelin Peptides, Precursors, and Endothelin-Converting Enzymes. , 2002, 206, 003-019.		2
49	Radioligand Binding Assays and Quantitative Autoradiography of Endothelin Receptors. , 2002, 206, 045-070.		8
50	Analysis of Endothelins by Enzyme-Linked Immunosorbent Assay and Radioimmunoassay. , 2002, 206, 021-036.		2
51	Effect of in vivo fetal infusion of dexamethasone at 0.75 GA on fetal ovine resistance artery responses to ET-1. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2001, 281, R261-R268.	0.9	44
52	Vasoconstrictor activity of novel endothelin peptide, ET-1(1-31), in human mammary and coronary arteries in vitro. <i>British Journal of Pharmacology</i> , 2001, 134, 1360-1366.	2.7	37
53	Orphan-receptor ligand human urotensin II: receptor localization in human tissues and comparison of vasoconstrictor responses with endothelin-1. <i>British Journal of Pharmacology</i> , 2000, 131, 441-446.	2.7	226
54	Endothelin-converting enzyme in human tissues. <i>The Histochemical Journal</i> , 1998, 30, 359-374.	0.6	29

#	ARTICLE	IF	CITATIONS
55	Characterization of [¹²⁵ I]-PD164333, an ETA selective non-peptide radiolabelled antagonist, in normal and diseased human tissues. British Journal of Pharmacology, 1998, 123, 223-230.	2.7	25
56	Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin ¹ , to distinguish between these agonists in binding experiments. British Journal of Pharmacology, 1996, 118, 335-342.	2.7	34
57	Endothelin ET _A and ET _B mRNA and receptors expressed by smooth muscle in the human vasculature: majority of the ET _A subtype. British Journal of Pharmacology, 1995, 114, 1110-1116.	2.7	149
58	[¹²⁵ I]â€PD 151242: a selective radioligand for human ET _A receptors. British Journal of Pharmacology, 1994, 111, 4-6.	2.7	72
59	Vasoconstrictor endothelin receptors characterized in human renal artery and vein <i>in vitro</i> . British Journal of Pharmacology, 1994, 113, 49-54.	2.7	55
60	[¹²⁵ I]â€PD151242: a selective ligand for endothelin ET _A receptors in human kidney which localizes to renal vasculature. British Journal of Pharmacology, 1994, 113, 1303-1310.	2.7	34
61	Characterization of two new ET _B selective radioligands, [¹²⁵ I]â€BQ3020 and [¹²⁵ I]â€[Ala ^{1,3,11,15}]ET ¹ in human heart. British Journal of Pharmacology, 1992, 107, 637-639.	2.7	60